Sitemap - 2023 - Provectus’s Substack

The Use of Provectus’s Rose Bengal Sodium as a Vaccine Adjuvant

Provectus Provides Updated PV-10 Data on Advanced Cutaneous Melanoma

Provectus Provides Updated PV-10 Data on Metastatic Uveal Melanoma

Provectus Files Form 10-Q for the Fiscal Quarter Ended September 30, 2023

Provectus’s PV-10 (rose bengal sodium) as a vaccine adjuvant

Provectus Announces Presentations at Upcoming Scientific and Medical Conferences

Statistical modeling of PV-10 and chemotherapy for FOLFIRINOX-refractory pancreatic cancer metastatic to the liver

Provectus's Pharmaceutical-Grade Small Molecule Immunotherapy Rose Bengal Sodium, Intratumoral Injection of Cancer, and Canine Soft Tissue Sarcomas

Provectus's 2023 Annual Stockholder Meeting

Cancer Immunotherapy PV-10's Innate Immune Signaling

Update: Provectus's Bascom Palmer Eye Institute's RBS-PDAT license option discussions are ongoing

Cancer immunotherapy PV-10’s evolution into a cancer immunotherapy

The Activity of Provectus’s Rose Bengal Sodium Drug Substance Against Colistin-Resistant Gram-Negative Bacteria

Provectus’s Rose Bengal Sodium: A “Proprietary” Molecule and Proprietary Drug Substance

Provectus's Use of Social Media Channels

The Impact of COVID-19 on Provectus’s Research & Development, Halogenated Xanthene Medical Science Platform, and Rose Bengal Sodium-based Investigational Drug & Drug Formulation Pipeline

Modern Rose Bengal Small Molecule: Drug Substance and API for 21st Century Drug Development

#nojs-banner { position: fixed; bottom: 0; left: 0; padding: 16px 16px 16px 32px; width: 100%; box-sizing: border-box; background: red; color: white; font-family: -apple-system, "Segoe UI", Roboto, Helvetica, Arial, sans-serif, "Apple Color Emoji", "Segoe UI Emoji", "Segoe UI Symbol"; font-size: 13px; line-height: 13px; } #nojs-banner a { color: inherit; text-decoration: underline; } This site requires JavaScript to run correctly. Please turn on JavaScript or unblock scripts